Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial.
Chin Med J (Engl) · 2025-Jun-20 · PMID 39385327
Time to deterioration in pain
Figure 4 Kaplan–Meier plots of TTD in mBPI-SF worst pain with increased analgesic use in (A) cohort A and (B) cohort B. TTD in pain was estimated using combined data from mBPI-SF and analgesic use, where deterioration in pain was defined as an increase of ≥2 points in mBPI-SF “worst pain” score from baseline (previously established as the minimally important difference), [26] or an increase of ≥1 level of analgesic drug class from baseline. † HR, stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ‡ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs. placebo + NSAI; § HR – stratified HR from Cox proportional hazard model and 95% CI by nature of disease; ¶ Log-rank stratified nominal P value (two-sided) for comparison of treatment vs . placebo + fulvestrant. 95% CI: 95% confidence interval; HR: Hazard ratio; mBPI-SF: Modified Brief Pain Inventory-Short Form; NSAI: Non-steroidal aromatase inhibitor; TTD: Time to deterioration; TTSD: Time to sustained deterioration.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-22T18:31:30+00:00 |